drugset / Trial / NCT05851456
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors
NaSingle-groupOpen-labelTreatment
Summary
20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory bone and soft tissue tumors.
Timeline
- Start
- 2023-04-10
- Primary completion
- 2025-04
- Completion
- 2026-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | R130 | Unknown | 1 ml | Other |
| Subject | R130 | Unknown | 6 ml | Other |